04 Aug

HEALTHBEACON SECURES OFFICIAL NHS SUPPLIER APPOINTMENT

Crown Commercial Service Supplier Logo - HealthBeaconDigital Health Company To Support UK NHSX Market With Remote Care Monitoring Service – Named Supplier For Crown Commercial Services (CCS)

Digital Health Company HealthBeacon is excited to announce they have been appointed as a supplier on the Crown Commercial Service (CCS)’s , SPARK Dynamic Purchasing System (DPS). The appointment, granted after a competitive process, provides HealthBeacon with direct access into the UK healthcare market supporting patients that manage injectable medications across therapeutic areas. The significant supply appointment will springboard the innovative med tech firms expansion across the NHS UK health network.

HealthBeacon responded to the NHSX’s further competition run via Crown Commercial Service’s (CCS) Spark Dynamic Purchasing System for companies to up-scale remote monitoring across the health service to support COVID-19 patients and management of people with long-term conditions for the next phases of the pandemic. HealthBeacon applied to the Spark DPS to provide Remote Monitoring Technology Platforms and includes both vital signs monitoring and out-patient support.

Improving Health Outcomes

The HealthBeacon Injection Care Management System™ offers digitally enabled remote care monitoring and support service for patients managing self-injectable medications across all therapeutic areas.

The self-injectable market for home administered medications is estimated to be over €60B globally.  However, one of the major challenges for people self-injecting medication is adhering to treatment schedules, resulting in both a significant loss to patient health and a rapidly escalating financial burden on state health care systems.

Evidence shows that, on average patients comply with their chronic medicine schedules only 50-60% of the time.  80% – 90% compliance can be achieved when medicines are connected with adherence support solutions – which is where HealthBeacon steps in.

HealthBeacon products are designed with patient empowerment at top priority which has led to 96% of patients accepting HealthBeacon products as part of their treatment.

Growth Opportunity

The self-injectable market for home administered medications is very large – consuming almost 16% of total annual drug spend. It is also the fastest growing component of the medicines market.

The CCS supports the public sector to achieve maximum commercial value when procuring common goods and services. In 2018/19, CCS helped the public sector to achieve commercial benefits worth £945m – supporting world-class public services that offer best value for taxpayers

In response to the rapidly changing COVID-19 landscape, HealthBeacon Injection Care Management System ™ enhanced its offering to help patients stay on track with critical medication, safely dispose used injection devices including a sustainable waste management service (HB Green Labs) limit unnecessary visits to the hospital and give the patient´s clinical team an excellent remote care monitoring opportunity relevant to each therapeutic area.

Speaking about this exciting development for HealthBeacon Malin Johansson, HealthBeacon, Vice President Europe, commented; “We are delighted to become a CCS supplier and welcome the opportunity to work with new providers and provide remote monitoring care support throughout the UK.  The spike in demand globally for remote support services from healthcare providers in response to Covid-19 pandemic highlights the importance of empowering and supporting patients remotely”.

Malin added; “We saw an opportunity to enhance our existing platform during the pandemic as a reliable and effective alternative for suppliers and patients requiring remote care during lockdown and ‘at risk’ phases as a result of the ever challenging current health landscape.   This is a significant opportunity for HealthBeacon as it provides a direct route into the UK Health market.  We looking forward to engaging with potential partners throughout the UK interested in working together

Jim Joyce, CEO and Co-Founder HealthBeacon, added “Patient empowerment is our top priority at HealthBeacon.  Our system has evolved to provide complete 360 care for patients on injectable medications.  We automated the process for adhering to medications so there is no longer the need to remember complicated schedules.  This enables the user with greater equanimity and increases health outcomes for patients and providers alike.”  

HealthBeacon embraces end to end sustainability and earlier this year launched Green Labs – its sustainable waste management service which reuses sharps bins and recycles injection waste.  Its world leading proprietary technology and new capabilities were designed to address the huge burden of healthcare waste globally, from its Irish hub with its online community.

Jim Joyce added; “Sustainable digital health technology has a huge role to play in future health empowering patients and improving health outcomes. HealthBeacon are committed to ensuring vulnerable patients adhere to medication and continue to access critical medications, safely.

 

24 Oct

HealthBeacon attends Johnson & Johnson, JLABS CEO Summit

HealthBeacon are delighted to attend the 2nd annual JLABs CEO Summit in sunny La Jolla, San Diego. 

The event has gathered partners of Johnson & Johnson’s, JLABs group for two days of networking and information exchange as well as talks and panel discussions with industry leaders. 

HealthBeacon has been part of the global JLABs network after being chosen as the winner of the Johnson & Johnson Innovation, JLABS and Janssen Supply Chain Group, LLC (JSC) Patient Adherence QuickFire Challenge earlier this year.

Since winning the QuickFire Challenge, HealthBeacon has achieved FDA clearance for it’s smart sharps bin and launched in an additional four markets including the U.S. so there is a lot to catch up on with old friends and new at the event. 

This coupled with the growth of our product portfolio and data analytics platform offers a clear point of intersection within the JLABs ecosystem.

Having completed day one of the event which was focussed on JPAL & Investor Partnering we are excited to partake in the CEO Summit main program which began tonight featuring talks from J&J executives, JLABS CEOs, investors and industry leaders, and continues on Wednesday 24th.